Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Aug;88(2):700-6.
doi: 10.1172/JCI115356.

Truncated forms of DNA-binding estrogen receptors in human breast cancer

G K Scott  1 , P Kushner, J L Vigne, C C Benz
Affiliations

Truncated forms of DNA-binding estrogen receptors in human breast cancer

G K Scott et al. J Clin Invest. 1991 Aug.

Abstract

The likelihood a breast cancer will respond to antiestrogen therapy depends on the tumor content of immunoreactive or ligand-binding estrogen receptor (ER). To investigate the failure of many ER-positive breast cancers to respond to antiestrogen therapy, we examined by gel-shift assay the ability of tumor ER to bind its cognate estrogen response element (ERE). Analysis of 38 primary breast cancers showed that some tumors containing abundant immunoreactive ER failed to demonstrate DNA binding ER. In many other ER-positive tumors, the fraction of DNA binding ER was low and consisted primarily of truncated receptor forms, which on Western analysis were revealed to be 50 kD homodimers and 67-50 kD ER heterodimers. The use of protease inhibitors during tumor extraction and the demonstration of nuclear-localizing ER and ERE-binding COUP (chicken ovalbumin upstream promoter) protein in these tumors indicated that the truncated forms of ER were likely present in vivo. The presence of intact DNA binding ER correlated with higher tumor content of immunoreactive sex steroid receptors (ER and/or PR), standard predictors of tumor responsiveness to antiestrogen, suggesting that loss or truncation of DNA binding ER may be an important prognostic parameter accounting for some forms of clinical resistance to antiestrogen therapy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Clin Invest. 1991 Mar;87(3):1123-6 - PubMed
    1. Cancer Res. 1991 Jan 1;51(1):105-9 - PubMed
    1. Cell. 1988 Oct 7;55(1):145-56 - PubMed
    1. Endocrinology. 1988 Nov;123(5):2540-8 - PubMed
    1. EMBO J. 1989 Jul;8(7):1981-6 - PubMed

Publication types